Compare BJ & BIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BJ | BIO |
|---|---|---|
| Founded | 1984 | 1952 |
| Country | United States | United States |
| Employees | N/A | 7450 |
| Industry | Department/Specialty Retail Stores | Biotechnology: Laboratory Analytical Instruments |
| Sector | Consumer Discretionary | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.6B | 10.1B |
| IPO Year | 2018 | 1994 |
| Metric | BJ | BIO |
|---|---|---|
| Price | $92.08 | $388.45 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 15 | 4 |
| Target Price | $108.36 | ★ $339.75 |
| AVG Volume (30 Days) | ★ 1.5M | 236.5K |
| Earning Date | 05-21-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 9.50 | ★ 142.61 |
| EPS | ★ 2.46 | N/A |
| Revenue | ★ $21,457,274,000.00 | $2,583,200,000.00 |
| Revenue This Year | $8.86 | $2.74 |
| Revenue Next Year | $6.50 | $3.20 |
| P/E Ratio | $36.58 | ★ N/A |
| Revenue Growth | ★ 4.66 | 0.65 |
| 52 Week Low | $83.21 | $236.73 |
| 52 Week High | $105.78 | $396.23 |
| Indicator | BJ | BIO |
|---|---|---|
| Relative Strength Index (RSI) | 45.91 | 58.50 |
| Support Level | $89.26 | $364.41 |
| Resistance Level | $95.56 | $385.71 |
| Average True Range (ATR) | 2.01 | 8.84 |
| MACD | -0.14 | -1.80 |
| Stochastic Oscillator | 38.63 | 59.76 |
BJ's Wholesale Club, founded in 1984, operates a membership-based warehouse club model primarily along the US East Coast, with roughly 260 clubs and a growing domestic presence across 21 states. In fiscal 2025, the company generated over $21 billion in revenue. BJ's offers a value-oriented assortment skewed toward grocery, perishables, and consumables (72% of sales), general merchandise (11%), and gasoline (17%). Its business model is supported by recurring membership fee income and private-label brands such as Wellsley Farms and Berkley Jensen.
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. In clinical diagnostics (60% of sales), Bio-Rad sells test systems and specialized quality controls for clinical laboratories. In life sciences (40% of sales), it develops and manufactures instruments and reagents used in research, biopharmaceutical production, and food testing and has a leadership position in dPCR technology. The company is geographically diverse, with major markets in the Americas (about 40% of sales), Europe (about 30%), Asia (about 30%), and other. Bio-Rad owns approximately 33% of Sartorius, a lab and bioprocessing supplier that specializes in single-use technology used in biologics manufacturing.